• broken image

    Analysis software of DaT-scan images

     

    DaTsoft3D®

     

  • Quantification tool for striatal SPECT images

    dedicated to quantitative clinical studies of Parkinson's syndromes

    Self-calibration of partial
    volume effect correction

     

    DaTsoft3D is able to automatically adapt it-self to the spatial resolution of DaT-scan images. The quantification values obtained are less dependent on the blurr, making it a useful tool for clinical studies.

    High performances
    and easy to use

     

    95% of sensitivity and specificity for the classification of healthy subjects versus Parkinson's disease patients based on the PPMI* international multicentre database.

  • Gives meaning to quantification

    by graphically locating the results from a database

    broken image

    White circle shows values obtained from the image of examined subject. Results from healthy subjects (green dots) and Parkinsonian subjects (red dots) of the PPMI* database are also displayed

    broken image

    A Parkinson Index (PI) is computed depending on putaminal binding ratios, the right / left asymmetry and age. PI value is displayed according to healthy subjects and Parkinson's patients PI distributions of the PPMI* database.

  • DaTsoft3D® features

     

    Data

    • Opening DaT-scan images in DICOM format, for one file or several files (for clinical studies)

    Reconstruction

    • Tomographic reconstruction by OSEMR iterative method for parallel collimation (fan-beam according to camera)

    Quantification

    • Semi-automatic registration on an extended 3D striatal model

    • Quantification of binding potential using partial volume effect correction

    Visualization

    • Simultaneous visualization of 3 planes and slice-by-slice visualisation (transverse or sagittal or coronal). 

    • Quantitative colour scales, with normalization based on the reference activity

    • Display the binding potentials of caudate nuclei and putamens with modified colour if the value is below the norm.

    • 2D graphs: Putamens vs Caudate nuclei and Putamens vs Dissymmetry

    • 1D graphs: Parkinson's Index taking into account subjects' age

    • Ability to add 2D graphics to a local database after quantification by DaTsoft3D

    Outputs

    • Automatically save results in a CSV file readable by Excel® for statistical analysis

    • Prints a screenshot with an automatic backup

     

  • broken image

     

    Try out DaTsoft3D

     

     

     

    Free trial license for 1 month**

    1. Download the installation file for Windows PC

    2. When running for the first time, the software will generate a license request file you must send us

    3. In return, you will receive within 48 hours your trial license valid for 1 month

     

  • FAQ

    Can I install DaTsoft3D on any computer?

    DaTsoft3D doesn’t depend on the gamma camera manufacturers. It works on computers with Windows® operating systems, versions 7 and higher. You must have administrator rights to install it. It requires 600 MB of RAM to run.

    How easy is it to adopt DaTsoft3D?

    It is very easy, it only takes a few minutes to go through the basic features.

    Is any documentation available?

    Yes, the software comes with a documentation which provides details on the action of each mouse click on the interface.

    How long has this software been used in hospitals?

    DaTsoft3D was installed in France in 2013 at Toulouse Purpan University Hospital Centre and at Marseille University Hospital Centre. Since then, it has also been installed in several other hospitals. Several thousand quantifications have been carried out with this software for clinical studies.

    More informations are available in the french section.

  • Publications

    Articles et communications

    1. Dopamine transporter imaging for the diagnosis of multiple system atrophy cerebellar type, 
      S Vergnet, F Hives, A Foubert-Samier, P Payoux, P Fernandez, M Meyer, J Dupouy, C Brefel-Courbon, F Ory-Magne, O Rascol, F Tison, A Pavy-Le Traon, WG. Meissner, Parkinsonism and Related Disorders, 2019, in press

    2. Système Veriton : évaluation quantitative sur fantôme de Jaszczak et sur fantôme striatalVeriton system: Quantitative evaluation based on Jaszczak and striatal phantom,
      E Cassol, P Gantet, P Payoux, Médecine Nucléaire, 2019, In press

    3. Dopaminergic loss in patients suspect of hydrocephalus, E Schmidt, F Ory-Magne, L Balardy, P Gantet, P Payoux, Fluids and Barriers of the CNS 2017, 14 (Suppl 1):A57.

    4. A longitudinal follow-up study of the quantification of dopamine transporters with 123IIoflupane (DaTscan).
      H Fayolle, P Gantet, AS Salabert, J Delrieu, C Brefel-Courbon, F Ory-Magne, T Voisin, P Payoux, Médecine Nucléaire, Volume 41, Issue 1, 2017, pp 36-41.

    5. Quantification of time-related decline of dopamine transporter from consecutive DaTscan images,
      H Fayolle, P Gantet, A Salabert, J Delrieu, C Brefel-Courbon, T Voisin, P Payoux, 29th Annual EANM Congress, Barcelone, octobre 2016

    6. Impact of gaussian post-filtering on DaTscan® cerebral SPECT quantitative analysis performance, 
      L Bosc, D Bourhis, R Abgral, PY Le Roux, P Robin, PY Salain, S Querellou, SNMMI, May 2016, San Diego (California), J Nucl Med, 57, supp 2, pp 36.

    7. Quantification auto-calibrée de la neurotransmission dopaminergique en TEMP : évaluation de DaTsoft3D,
      P Gantet, E Guedj, P Payoux, 52ème colloque de médecine nucléaire de langue française, St Etienne, mai 2014. Médecine Nucléaire, 2014, 38, 3, pp 33.

    8. DaTsoft3D: Self-calibrated software for dopamine transporter quantification in SPECT imaging - preliminary results,
      P Gantet, E Guedj, P Payoux, 3rd European Conference on Clinical Neuroimaging, Lille, mars 2014. 

  •  

    *About PPMI Database

    PPMI – a public-private partnership – is funded by the Michael J. Fox Foundation for Parkinson’s Research and funding partners, including: Abbvie, AVID, Biogen Idec, Biolegend, Bristol-Myers Squibb, GE Healthcare, Genentech, GSK, Lilly, Lundbeck, Merck, Mezo Scale Discovery, Pfizer, Piramal, Roche, Sanofi Genzyme, Servier, Takeda, Teva, UCB and Golub Capital. For more information, visit: www.ppmi-info.org.

     

    ** About trial licence

    Only one trial licence per institution will be granted.